血型抗原Lewis A和Lewis X在甲状腺乳头状癌中的表达

目的 :探讨血型抗原LewisA和LewisX在甲状腺乳头状癌中表达的意义。方法 :采用免疫组织化学EnVision方法 ,测定血型抗原LewisA和LewisX在 70例甲状腺乳头状癌和 70例癌旁正常甲状腺滤泡上皮 ,以及 16例甲状腺滤泡性腺瘤、17例结节性甲状腺肿和 14例桥本氏甲状腺炎中的表达。结果 :LewisA和LewisX在甲状腺乳头状癌中的表达阳性率分别为 94 3% ( 66/ 70 )和 85 7% ( 60 / 70 ) ,癌旁正常甲状腺滤泡上皮中的表达阳性率分别为 2 9% ( 2 / 70 )和 5 7% ( 4 / 70 )。肿瘤直径≥ 1cm组LewisX的表达强度较肿瘤直径 <1cm组明显增高 ,P <0 0 1。淋巴结转移组LewisX的表达强度较非转移组显著增高 ,P <0 0 1。结论 :LewisA和LewisX可作为诊断甲状腺乳头状癌的参考指标。LewisX的表达强度与肿瘤浸润及转移有关     

ABH(O)血型抗原与恶性肿瘤相关性研究

目的　找出恶性肿瘤ABH(O)血型抗原 (Bloodgroupantigens,以下简称BGA)的丢失与恶性肿瘤的发病特点及相互关系。方法　采用免疫组化方法检测 70例恶性肿瘤患者BGA表达情况 ,分析BGA的表达与肿瘤淋巴结转移、血行转移的关系 ,从而找出相互规律 .结果　 70例恶性肿瘤标本中 ,肿瘤BGA表达阳性者 39例 (5 5 .7% ) ;肿瘤BGA表达阴性者 31例 (44 .3% ) ,BGA表达与肿瘤分化程度及有无淋巴结或血行转移之间有显著差异 (P〈0 .0 1或 0 .0 0 5 )。结论　肿瘤ABH(O)抗原的异常表达与肿瘤的转移、复发和预后有密切的关系。     

肺癌组织中HLA—DR抗原表达的临床意义

目的探讨HLA-DR抗原在肺癌中的表达及其临床意义.方法采用免疫组化ABC法检测57例原发性肺癌组织中HLA-DR抗原表达情况,并分析了该抗原表达与肺癌临床病理的关系.结果 57例肺癌组织中,腺癌、鳞癌和大细胞未分化癌的阳性表达率分别为72.0%、42.1%和28.6%,6例小细胞未分化癌(SCLC)和20例癌旁组织均未见阳性表达.腺癌的阳性率明显高于鳞癌和大细胞未分化癌(P<0.05).随着肿瘤进展,HLA-DR表达逐渐降低,Ⅰ期和Ⅱ Ⅲ期之间其阳性率差异有显著性(P<0.05),分化程度高的肺癌HLA-DR阳性表达率明显高于中、低分化程度的肺癌(P<0.01).HLA-DR表达与肺癌有无淋巴结转移无明显相关性(P>0.05).结论 HLA-DR异常表达可能是肺癌发生和发展过程中的标志物之一,对判断肺癌患者的生物学行为具有一定的意义.     

肺癌细胞的HLA抗原表达与组织类型及免疫修饰

目的 了解肺癌细胞的ＨＬＡ抗原表达及肺癌的组织类型和免疫饰对其的影响。方法 采用免疫组织化学方法和流式细胞术从体探讨肺癌组织的ＨＬＡ－ＤＲ抗原表达。结果 在５６例病理确诊的肺癌患者癌组织中,腺癌７６％（２３／２９）,鳞癌８％（２／２４）表达为ＨＬＡ－ＤＲ抗原阳性,而３例小细胞癌均为阴性。腺癌的阳必同于鳞癌和小细胞癌（Ｐ〈０．０５）。ＨＡＬ－ＤＲ抗原阳性癌细胞周围可见较多的淋巴细胞浸润,二者呈明显的     

Napsin A在肺腺癌中的表达及临床意义

目的探讨Napsin A对肺腺癌的诊断价值及与肺腺癌分化程度、临床病期和淋巴结转移的关系。方法采用SP免疫组织化学方法检测47例肺腺癌患者的肺癌组织中Napsin A的表达,并与癌旁正常肺组织、46例其他组织学类型的肺癌组织和19例良性肿瘤组织对比。结果肺腺癌组Napsin A表达阳性率87．2％,显著高于非肺腺癌组4．3％(X2=64．249,P<0．01)和良性肿瘤组21．1％(X2=27．317,P<0．01),但低于正常肺组织组100％(P<0．05);高分化、中分化和低分化肺腺癌组织中Napsin A表达阳性率分别为100％(20／20)、86．7％(13／15)和66．7％ (8／12),三者的阳性率具有显著性差异(X2=7．489,P<0．05);Ⅰ～Ⅱ期腺癌组Napsin A表达阳性率为100％(24／24),明显高于Ⅲ-Ⅳ期腺癌组73．9％(17／23),P<0．01;有淋巴结转移的肺腺癌组织Napsin A表达阳性率为72．7％(16／22),明显低于无淋巴结转移者100％(25／25),P< 0．05。结论Napsin A可以作为诊断肺腺癌的特异性肿瘤标记物,是判断肺腺癌恶性程度、临床病期及有无淋巴结转移的重要指标。     

Napsin A在肺腺癌中的表达及临床意义

目的探讨Napsin A对肺腺癌的诊断价值及与肺腺癌分化程度、临床病期和淋巴结转移的关系。方法采用SP免疫组织化学方法检测47例肺腺癌患者的肺癌组织中Napsin A的表达,并与癌旁正常肺组织、46例其他组织学类型的肺癌组织和19例良性肿瘤组织对比。结果肺腺癌组Napsin A表达阳性率87．2％,显著高于非肺腺癌组4．3％（x^2=64．249,P〈0．01）和良性肿瘤组21．1％（x^2=27．317,P〈0．01）,但低于正常肺组织组100％（P〈0．05）;高分化、中分化和低分化肺腺癌组织中Napsin A表达阳性率分别为100％（20／20）、86．7％（13／15）和66．7％（8／12）,三者的阳性率具有显著性差异（x^2=7．489,P〈0．05）;Ⅰ～Ⅱ期腺癌组NapsinA表达阳性率为100％（24／24）,明显高于Ⅲ～Ⅳ期腺癌组73．9％（17／23）,P〈0．01;有淋巴结转移的肺腺癌组织Napsin A表达阳性率为72．7％（16／22）,明显低于无淋巴结转移者100％（25／25）,P〈0．05。结论Napsin A可以作为诊断肺腺癌的特异性肿瘤标记物,是判断肺腺癌恶性程度、临床病期及有无淋巴结转移的重要指标。     

DLL4、VEGF在肺腺癌中的表达及其与肿瘤血管生成的关系

背景与目的 血管发生(angiogenesis)依赖于多种促进血管发生因子和抑制血管发生因子的综合交互作用调控.血管内皮生长因子(VEGF)和Notch信号传递途径(Notch signaling palhway)参与了此过程.本研究旨在探讨肺腺痛组织中Notch配体DLL4、VEGF的表达及其与肺腺癌血管生成的关系及临床意义.方法 应用免疫组织化学方法检测80例肺腺癌(包括细支气管肺泡癌和普通肺腺癌)石蜡切片组织中DLL4、VEGF和CD34的表达.结果 DLIM、VEGF的表达与肺腺痛患者的肿瘤直径、临床分期、组织学分级.淋巴结转移密切相关,DLL4阳性表达病例中VEGF表达率明显比DLLA阴性表达病例高,DLL4、VEGF共表达时与微血管密度的相关性比DLL4单独表达更明显.DLL4的表达在普通肺腺癌中明显高于细支气管肺泡癌.结论 肺腺癌的预后与血管生成明显相关,DLL4的高表达与肺腺癌转移预后密切相关.     

LKB1蛋白在肺腺癌组织中的表达及临床意义

目的：了解LKB1蛋白在肺腺癌组织中表达的临床意义.方法：应用免疫组化法检测62例肺腺癌组织中LKB1蛋白表达情况.结果：LKB1蛋白在肺腺癌细胞及正常肺支气管上皮均有表达,弥漫性分布于细胞质,细胞核亦有表达.肺腺癌组织中LKB1蛋白表达的阴性率为38.7%（24/62）.LKB1的表达与肺腺癌TNM分期中的淋巴结转移（N）及临床分期有显著的相关性,X^2=10.620,P=0.014;X^2=18.635,P=0.000.LKB1蛋白阴性组预后较差,中位生存期为15个月,而LKB1阳性组的中位生存时间为29个月,两者比较差异有统计学意义,X^2=1 5.350,P=0.000.结论：LKB1蛋白表达下降与肺腺癌发生淋巴结转移相关,是肺腺癌预后不良的风险因素之一.     

Expression of Lewis(a), Lewis(b), and sialated Lewis(a) antigens in early and advanced human gastric cancers

An immunohistochemical analysis of the expression of Lewis(a), Lewis(b), and sialated Lewis(a) blood group antigens was performed on specimens of human non-involved stomach (n = 91), early gastric cancers (n = 41), and advanced gastric cancers (n = 50). In non-involved stomach, Lewis(a) and Lewis(b) were detected mainly in surface epithelium, although sialated Lewis(a) was scarcely expressed. These blood group-related antigens were rarely observed in deep glands. In gastric cancers, Lewis(a) showed a tendency to be expressed in well or moderately differentiated carcinomas, and this was observed to be more marked in advanced tumors. There was no obvious difference in positive ratios of Lewis(b) between degrees of differentiation of the cancers. Sialated Lewis(a) was not detected in early cancers, and its frequent expression in well- or moderately differentiated, advanced carcinomas suggested an association with both cancer differentiation and progression. These results indicate that knowledge of the expression of blood group antigens may help interpret the antigenic alterations occurring in the course of carcinogenesis, differentiation, and progression of gastric cancers.     

ABO (H) cell surface antigens in benign and malignant parotid neoplasms

Twenty-two inflammatory, benign, or malignant parotid lesions were studied by means of the specific red cell adherence test (SRCA), a modification of the Coombs' mixed cell agglutination reaction. In 22 normal parotid tissues the acinar structures were devoid of red cell agglutination, but it was present in ductal epithelium. Findings were similar in 2 cases of parotitis, 11 benign mixed tumors, and 1 malignant mixed tumor. All lacked red cell agglutination in areas of neoplastic change. Benign Warthin's tumors (4 cases) demonstrated antigenicity in the columnar epithelial component of the tumor, but lacked red cell agglutination in areas of the lymphoid component. One malignant Warthin's tumor showed agglutination in areas of normal columnar epithelium but not in areas of malignant dedifferentiation. Undifferentiated carcinoma (1 case) and adenoid cystic carcinoma (2 cases) did not possess detectable ABO (H) antigens in neoplastic areas of the gland. The absence of ABO antigens in normal acinar glands supports their suggested myoepithelial or mesenchymal derivation, as the absence of antigen in benign and malignant mixed tumors supports their proposed mesenchymal derivation. Ductular epithelium and the epithelial components of benign Warthin's tumors have ABO (H) antigens, while the loss of antigen in the epithelial portion of the malignant Warthin's tumor is characteristic of epithelial neoplastic dedifferentiation. Loss of antigen in adenoid cystic and undifferentiated carcinomas of the parotid supports the concept that antigen is absent in epithelially derived malignant neoplasms.     

P53、ras基因在肺腺癌组织中的表达及意义

目的　了解P5 3基因及ras基因在肺腺癌中的表达特点及与预后的关系。方法　采用免疫组化法对 5 3例肺腺癌组织中P5 3及ras蛋白进行检测 ,分组随访。结果　肺腺癌组织中P5 3、ras蛋白阳性表达率分别为 5 4.72 %、6 6 .38% ,淋巴结转移组阳性表达率 (78.13 %、84.38% )高于无淋巴结癌转移组 ;低分化者阳性表达率 (81.82 %、86 .36 % )高于高分化组 ;阴性组 1年存活率高于阳性组。结论　P5 3、ras表达和肺腺癌生物学行为有关 ,可作为判断预后的参考指标。     

中国人ABO血型与肺癌发生关系的Meta分析

目的：从循证医学的角度评价中国人群ABO血型与肺癌之间的相互关系。方法：采用Meta分析专用软件Review Manager 5．0对20年内中国不同地区发表的15篇关于 ABO 血型与肺癌关系的病例-对照研究进行 Meta 分析。结果：中国人 ABO 血型与肺癌发生无关。A、B、O、AB 血型的OR值分别是1．03（0．80，1．32）、0．98（0．87，1．12）、0．94（0．73，1．2）、0．95（0．83，1．08）。A、B、O、AB血型在肺癌人群与正常人群中的分布没有差别，P值分别为0．82、0．81、0．63、0．43，均大于0．05，均无统计学意义。结论：肺癌是一种多因素疾病，单一的ABO血型因素可能与肺癌发生是无关的。     

CD44v6和E-cadherin表达与乳腺癌生物学行为的关系

目的 :探讨CD4 4v6和E cadherin(E Cad)表达与乳腺癌临床病理生物学行为的关系 ,以及它们之间的相关性。方法 :应用催化信号放大系统免疫组化方法 ,对 94例乳腺癌组织进行CD4 4v6和E Cad蛋白检测。结果 :CD4 4v6阳性表达及E Cad阴性表达均与乳腺癌的组织学分级、临床分期、淋巴结转移、复发和预后呈正相关 (P <0 0 5 )。乳腺癌中CD4 4v6表达与E Cad表达呈负相关 (P <0 0 5 )。结论 :CD4 4v6表达与E Cad表达具有负调节的协同作用。CD4 4v6和E Cad表达对估计乳腺癌淋巴结转移及患者生存期有重要意义 ,可作为判断乳腺癌的转移和预后的参考指标     

Association of ABO Blood Group and Risk of Lung Cancer in a Multicenter Study in Turkey

Background: The ABO blood groups and Rh factor may affect the risk of lung cancer. Materials and Methods:We analyzed 2,044 lung cancer patients with serologically confirmed ABO/Rh blood group. A group of 3,022,883healthy blood donors of Turkish Red Crescent was identified as a control group. We compared the distributionsof ABO/Rh blood group between them. Results: The median age was 62 years (range: 17-90). There was a clearmale predominance (84% vs. 16%). Overall distributions of ABO blood groups were significantly differentbetween patients and controls (p=0.01). There were also significant differences between patients and controls withrespect to Rh positive vs. Rh negative (p=0.04) and O vs. non-O (p=0.002). There were no statistically significantdifferences of blood groups with respect to sex, age, or histology. Conclusions: In the study population, ABOblood types were associated with the lung cancer. Having non-O blood type and Rh-negative feature increasedthe risk of lung cancer. However, further prospective studies are necessary to define the mechanisms by whichABO blood type may influence the lung cancer risk.     

ABO blood group and incidence of epithelial ovarian cancer

Previous studies have observed an association between ABO blood group and risk of certain malignancies, including ovarian cancer; however, no prospective studies of the association with ovarian cancer risk are available. Using data from 49,153 women in the Nurses' Health Study, we examined the association between ABO blood group and incidence of epithelial ovarian cancer. Study participants reported their blood type and Rh factor in 1996, and 234 women were diagnosed with incident ovarian cancer during 10 years of follow‐up. We used Cox proportional hazards regression to model the incidence rate ratios (RR) and 95% confidence intervals (CI) of ovarian cancer for each blood group category. Compared to women with blood group O, women with blood group AB or B had a nonsignificant 38% increase in ovarian cancer incidence (95% CI = 0.88–2.16 for blood group AB and 0.96–1.99 for blood group B), whereas blood group A was not associated with risk (RR = 0.95, 95% CI = 0.70–1.30). Combining blood groups AB and B, we observed a statistically significant positive association with presence versus absence of the B antigen overall (RR = 1.41, 95% CI = 1.06–1.88) and for the serous invasive subtype (RR = 1.53, 95% CI = 1.08–2.17). In this large, prospective cohort of women, presence of the B antigen was positively associated with ovarian cancer incidence, whereas blood group A was not associated with risk. Additional studies are needed to confirm this association and to explore the mechanisms through which blood group may influence ovarian cancer risk.     

血管内皮生长因子-C的表达与宫颈癌生物学行为的关系

目的研究VEGF-C表达与宫颈癌临床病理生物学行为的关系。方法免疫组化S-P法检测59例宫颈癌手术标本中VEGF-C蛋白表达情况。结果宫颈癌中VEGF-C蛋白表达率为66.1%(39/59),与盆腔淋巴结转移显著相关(P=0.005)。但与年龄、国际妇产科联盟(FI-GO)分期、组织学类型、组织学分级和肿瘤直径无关。VEGF-C表达阳性组5年生存率显著低于阴性组(P=0.006)。结论宫颈癌组织中VEGF-C蛋白表达与宫颈癌侵袭转移和预后有关,检测VEGF-C对了解宫颈癌生物学行为和评估预后具有一定的临床价值。